Related Experiment Video
Updated: Jan 6, 2026
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Identification of C4BPA as a genetically informed drug target in NSCLC: an integrative single-cell and multi-omics
Zhihan Xiao1, Xinji Liu1, Wei Tang1
1Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Background:
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Despite advancements in treatment, drug resistance and limited therapeutic efficacy persist, underscoring the urgent need for novel and mechanistically informed therapeutic strategies. Identifying genetically supported drug targets may accelerate the development of precision therapies in NSCLC.
Methods:
We implemented an integrative multi-omics framework combining single-cell RNA sequencing (scRNA-seq), genome-wide association studies (GWAS), and molecular quantitative trait locus (QTL) datasets including expression (eQTL), protein (pQTL), and DNA methylation (mQTL) QTLs. Druggable candidates were systematically evaluated using a suite of Mendelian randomization (MR) approaches-including summary data-based MR (SMR), generalized SMR (GSMR), and genetic risk score (GRS) analysis. Epigenetic regulation and downstream signaling were further explored through mediation MR analysis.
Results:
C4BPA, a complement-regulatory macromolecule, emerged as a risk factor for NSCLC across multiple MR models, with consistent findings validated at both transcriptomic and proteomic levels. Epigenetic activation of C4BPA via DNA methylation was observed, and C4BPA expression was shown to promote NSCLC progression through the inflammatory chemokine CCL8 signaling axis. Sensitivity analyses confirmed the robustness of association inference.
Conclusions:
Our findings identify C4BPA as a genetically validated and biologically plausible therapeutic target for NSCLC. This study demonstrates the power of integrating single-cell transcriptomics with population-scale omics and association inference to uncover actionable targets, offering a scalable framework for advancing precision oncology in lung cancer.
Insights
Complement component 4 binding protein alpha (C4BPA) is identified as a novel therapeutic target for non-small cell lung cancer (NSCLC). This discovery offers a new avenue for precision oncology in lung cancer treatment.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Non-small cell lung cancer (NSCLC) presents a significant global health challenge due to persistent drug resistance and limited treatment efficacy.
- There is a critical need for novel therapeutic strategies informed by genetic insights to improve precision medicine in NSCLC.
- Identifying genetically validated drug targets is crucial for accelerating the development of effective NSCLC therapies.
Purpose of the Study:
- To identify novel, genetically supported therapeutic targets for non-small cell lung cancer (NSCLC).
- To leverage an integrative multi-omics approach combined with Mendelian randomization (MR) to uncover actionable targets.
- To explore the biological mechanisms underlying target engagement and downstream signaling pathways.
Main Methods:
- Integrated single-cell RNA sequencing (scRNA-seq) with genome-wide association studies (GWAS) and molecular quantitative trait locus (QTL) data (eQTL, pQTL, mQTL).
- Employed Mendelian randomization (MR) methods, including SMR, GSMR, and GRS analysis, to evaluate druggable candidates.
- Utilized mediation MR analysis to investigate epigenetic regulation and downstream signaling pathways.
Main Results:
- Complement component 4 binding protein alpha (C4BPA) was consistently identified as a risk factor for NSCLC across multiple MR models.
- Transcriptomic and proteomic data validated C4BPA's association with NSCLC risk.
- Epigenetic activation of C4BPA via DNA methylation was observed, promoting NSCLC progression through the CCL8 signaling axis.
Conclusions:
- C4BPA is a genetically validated and biologically plausible therapeutic target for NSCLC.
- The study highlights the integration of single-cell transcriptomics and population-scale omics for target discovery.
- A scalable framework is proposed for advancing precision oncology in lung cancer through robust target identification.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...